Drug-Induced Thrombotic Microangiopathy

ABSTRACT

Drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (TTP/HUS) has been recognized for several years. The most commonly implicated drugs are mitomycin-C, cyclosporine, quinine, and ticlopidine. As with idiopathic cases of TTP/HUS, basic science discoveries in the late 1990s now suggest that the likely mechanisms by which these agents lead to a thrombotic microangiopathy (TMA) include either an immune-mediated phenomenon involving the ADAMTS13 metalloprotease or direct endothelial toxicity. This article reviews the current understanding of the pathogenesis, the clinical and laboratory features, and the recommended treatments, prognosis, and outcomes of drug-associated TMA.

Thrombotic microangiopathy - thrombotic thrombocytopenic purpura - hemolytic uremic syndrome - drug toxicity

REFERENCES

• 1 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.  Proc NY Pathol Soc. 1924;  24 21-24
• 2 Vesely S K, George J N, Lämmle B et al.. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.  Blood. 2003;  102 60-68
• 3 Zheng X L, Kaufman R M, Goodnough L T, Sadler J E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.  Blood. 2004;  103 4043-4049
• 4 Veyradier A, Obert B, Houllier A et al.. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.  Blood. 2001;  98 1765-1772
• 5 Miller D P, Kaye J A, Shea K et al.. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome.  Epidemiology. 2004;  15 208-215
• 6 Sadler J E, Moake J L, Miyata T, George J N. Recent advances in thrombotic thrombocytopenic purpura.  Hematology (Am Soc Hematol Educ Program). 2004;  407-423
• 7 Lian EC-Y. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.  Semin Thromb Hemost. 2005;  31 625-632
• 8 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1435
• 9 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.  Blood. 1996;  87 4223-4234
• 10 Tsai H M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.  Blood. 1996;  87 4235-4244
• 11 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.  Nature. 2001;  413 488-494
• 12 Furlan M, Robles R, Galbusera M et al.. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med. 1998;  339 1578-1584
• 13 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 1585-1594
• 14 Medina P J, Sipols J M, George J N. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.  Curr Opin Hematol. 2001;  8 286-293
• 15 Gottschall J L, Elliot W, Lianos E et al.. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity.  Blood. 1991;  77 306-310
• 16 Tsai H M, Rice L, Sarode R et al.. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.  Ann Intern Med. 2000;  132 794-799
• 17 Mauro M, Zlatopolskiy A, Raife T J, Laurence J. Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades.  Br J Haematol. 2004;  124 200-210
• 18 Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose.  Cancer. 1985;  55 47-50
• 19 Lesesne J B, Rothschild N, Erickson B et al.. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.  J Clin Oncol. 1989;  7 781-789
• 20 Leach J W, Pham T, Diamandidis D, George J N. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): a case report.  Am J Hematol. 1999;  61 268-270
• 21 Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian H M. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?.  Cancer. 1999;  85 2583-2588
• 22 Al-Zahrani H, Gupta V, Minden M D et al.. Vascular events associated with alpha interferon therapy.  Leuk Lymphoma. 2003;  44 471-475
• 23 Humphreys B D, Sharman J P, Henderson J M et al.. Gemcitabine-associated thrombotic microangiopathy.  Cancer. 2004;  100 2664-2670
• 24 Gordon L I, Kwaan H C. Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient.  Semin Thromb Hemost. 1999;  25 217-221
• 25 Cantrell Jr J E, Phillips T M, Schein P S. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy.  J Clin Oncol. 1985;  3 723-734
• 26 Proia A D, Harden E A, Silberman H R. Mitomycin-induced hemolytic-uremic syndrome.  Arch Pathol Lab Med. 1984;  108 959-962
• 27 Doll D C, Weiss R B, Issell B F. Mitomycin: ten years after approval for marketing.  J Clin Oncol. 1985;  3 276-286
• 28 Nagaya S, Wada H, Oka K et al.. Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C.  Am J Hematol. 1995;  50 237-243
• 29 Fung M C, Storniolo A M, Nguyen B et al.. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.  Cancer. 1999;  85 2023-2032
• 30 Walter R B, Joerger M, Pestalozzi B C. Gemcitabine-associated hemolytic-uremic syndrome.  Am J Kidney Dis. 2002;  40 E16
• 31 Al Aly Z, Philoctete Ashley J M, Gellens M E, Gonzalez E A. Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence?.  Am J Kidney Dis. 2005;  45 762-768
• 32 Helmly R B, Bergin J J, Shulman N R. Quinine-induced purpura. Observation on antibody titers.  Arch Intern Med. 1967;  120 59-62
• 33 Gottschall J L, Neahring B, McFarland J G et al.. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature.  Am J Hematol. 1994;  47 283-289
• 34 Maguire R B, Stroncek D F, Campbell A C. Recurrent pancytopenia, coagulopathy, and renal failure associated with multiple quinine-dependent antibodies.  Ann Intern Med. 1993;  119 215-217
• 35 Kojouri K, Vesely S K, George J N. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes.  Ann Intern Med. 2001;  135 1047-1051
• 36 Baliga R S, Wingo C S. Quinine induced HUS-TTP: an unusual presentation.  Am J Med Sci. 2003;  326 378-380
• 37 PDR for Herbal Medicines .1st ed. Montvale, NJ; Medical Economics Co 1998
• 38 Reynolds J C, Agodoa L Y, Yuan C M, Abbott K C. Thrombotic microangiopathy after renal transplantation in the United States.  Am J Kidney Dis. 2003;  42 1058-1068
• 39 George J N, Li X, McMinn J R et al.. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma.  Transfusion. 2004;  44 294-304
• 40 Jeejeebhoy F M, Zaltzman J S. Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy.  Transplantation. 1998;  65 1645-1648
• 41 Ramasubbu K, Mullick T, Koo A et al.. Thrombotic microangiopathy and cytomegalovirus in liver transplant recipients: a case-based review.  Transpl Infect Dis. 2003;  5 98-103
• 42 Schwimmer J, Nadasdy T A, Spitalnik P F et al.. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy.  Am J Kidney Dis. 2003;  41 471-479
• 43 Singh N, Gayowski T, Marino I R. Hemolytic uremic syndrome in solid-organ transplant recipients.  Transpl Int. 1996;  9 68-75
• 44 Zarifian A, Meleg-Smith S, O'Donovan R et al.. Cyclosporine-associated thrombotic microangiopathy in renal allografts.  Kidney Int. 1999;  55 2457-2466
• 45 Trimarchi H M, Truong L D, Brennan S et al.. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature.  Transplantation. 1999;  67 539-544
• 46 Wiener Y, Nakhleh R E, Lee M W et al.. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome.  Clin Transplant. 1997;  11 157-162
• 47 Zent R, Katz A, Quaggin S et al.. Thrombotic microangiopathy in renal transplant recipients treated with cyclosporin A.  Clin Nephrol. 1997;  47 181-186
• 48 McCauley J, Bronsther O, Fung J et al.. Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506.  Lancet. 1989;  2 1516
• 49 Myers J N, Shabshab S F, Burton N A, Nathan S D. Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome.  J Heart Lung Transplant. 1999;  18 1024-1026
• 50 Pham P T, Peng A, Wilkinson A H et al.. Cyclosporine and tacrolimus-associated thrombotic microangiopathy.  Am J Kidney Dis. 2000;  36 844-850
• 51 Abraham K A, Little M A, Dorman A M, Walshe J J. Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus.  Transpl Int. 2000;  13 443-447
• 52 Hochstetler L A, Flanigan M J, Lager D J. Transplant-associated thrombotic microangiopathy: the role of IgG administration as initial therapy.  Am J Kidney Dis. 1994;  23 444-450
• 53 Iacopino P, Pucci G, Arcese W et al.. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO).  Bone Marrow Transplant. 1999;  24 47-51
• 54 Elliott M A, Nichols Jr W L, Plumhoff E A et al.. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.  Mayo Clin Proc. 2003;  78 421-430
• 55 Arai S, Allan C, Streiff M et al.. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy.  Hematol J. 2001;  2 292-299
• 56 Palestine A G, Austin III H A, Balow J E et al.. Renal histopathologic alterations in patients treated with cyclosporine for uveitis.  N Engl J Med. 1986;  314 1293-1298
• 57 Rodriguez F, Krayenbuhl J C, Harrison W B et al.. Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry.  Arthritis Rheum. 1996;  39 1491-1498
• 58 Holler E, Kolb H J, Hiller E et al.. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation.  Blood. 1989;  73 2018-2024
• 59 Zoja C, Furci L, Ghilardi F et al.. Cyclosporin-induced endothelial cell injury.  Lab Invest. 1986;  55 455-462
• 60 Brown Z, Neild G H. Cyclosporine inhibits prostacyclin production by cultured human endothelial cells.  Transplant Proc. 1987;  19(1 pt 2) 1178-1180
• 61 Garcia-Maldonado M, Kaufman C E, Comp P C. Decrease in endothelial cell-dependent protein C activation induced by thrombomodulin by treatment with cyclosporine.  Transplantation. 1991;  51 701-705
• 62 Pham P T, Danovitch G M, Wilkinson A H et al.. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient.  Transplantation. 2002;  74 1077-1080
• 63 Roberts P, Follette D, Allen R et al.. Cyclosporine A-associated thrombotic thrombocytopenic purpura following lung transplantation.  Transplant Proc. 1998;  30 1512-1513
• 64 Schmidt R J, Venkat K K, Dumler F. Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression.  Transplant Proc. 1991;  23 3156-3157
• 65 Burke G W, Ciancio G, Cirocco R et al.. Microangiopathy in kidney and simultaneous pancreas/kidney recipients treated with tacrolimus: evidence of endothelin and cytokine involvement.  Transplantation. 1999;  68 1336-1342
• 66 Randhawa P S, Tsamandas A C, Magnone M et al.. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy.  Am J Surg Pathol. 1996;  20 306-312
• 67 Moutabarrik A, Ishibashi M, Fukunaga M et al.. FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro.  Transplant Proc. 1991;  23 3133-3136
• 68 Nakazawa Y, Hashikura Y, Urata K et al.. Von Willebrand factor-cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation: a case report.  Liver Transpl. 2003;  9 1328-1333
• 69 Tripodi A, Chantarangkul V, Bohm M et al.. Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas.  J Thromb Haemost. 2004;  2 1601-1609
• 70 Gharpure V S, Devine S M, Holland H K et al.. Thrombotic thrombocytopenic purpura associated with FK506 following bone marrow transplantation.  Bone Marrow Transplant. 1995;  16 715-716
• 71 Lin C C, King K L, Chao Y W et al.. Tacrolimus-associated hemolytic uremic syndrome: a case analysis.  J Nephrol. 2003;  16 580-585
• 72 Savi P, Herbert J M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.  Semin Thromb Hemost. 2005;  31 174-183
• 73 Evens A M, Kwaan H C, Kaufman D B, Bennett C L. TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology.  Transplantation. 2002;  74 885-887
• 74 Page Y, Tardy B, Zeni F et al.. Thrombotic thrombocytopenic purpura related to ticlopidine.  Lancet. 1991;  337 774-776
• 75 Bennett C L, Weinberg P D, Rozenberg-Ben-Dror K et al.. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases.  Ann Intern Med. 1998;  128 541-544
• 76 Steinhubl S R, Tan W A, Foody J M, Topol E J. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting.  JAMA. 1999;  281 806-810
• 77 Bennett C L, Davidson C J, Raisch D W et al.. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention.  Arch Intern Med. 1999;  159 2524-2528
• 78 [No authors listed] . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.  Lancet. 1996;  348 1329-1339
• 79 Yusuf S, Zhao F, Mehta S R et al.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.  N Engl J Med. 2001;  345 494-502
• 80 Bennett C L, Connors J M, Carwile J M et al.. Thrombotic thrombocytopenic purpura associated with clopidogrel.  N Engl J Med. 2000;  342 1773-1777
• 81 Chinnakotla S, Leone J P, Fidler M E et al.. Clopidogrel-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in a kidney/pancreas transplant recipient.  Transplantation. 2000;  70 550-552
• 82 Nara W, Ashley I, Rosner F. Thrombotic thrombocytopenic purpura associated with clopidogrel administration: case report and brief review.  Am J Med Sci. 2001;  322 170-172
• 83 Zakarija A, Bandarenko N, Pandey D K et al.. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration.  Stroke. 2004;  35 533-537
• 84 Manor S M, Guillory G S, Jain S P. Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting.  Pharmacotherapy. 2004;  24 664-666
• 85 Andersohn F, Hagmann G, Garbe E. Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases.  Heart. 2004;  90 e57
• 86 von Mach M A, Eich A, Weilemann L S, Munzel T. Subacute coronary stent thrombosis in a patient developing clopidogrel associated thrombotic thrombocytopenic purpura.  Heart. 2005;  91 e14
• 87 Orimo S, Ozawa E, Yagi H et al.. Simple plasma exchange reduced autoantibody to von Willebrand factor-cleaving protease in a Japanese man with ticlopidine-associated thrombotic thrombocytopenic purpura.  J Intern Med. 2002;  251 280-281
• 88 Sugio Y, Okamura T, Shimoda K et al.. Ticlopidine-Associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity.  Int J Hematol. 2001;  74 347-351
• 89 Chen D K, Kim J S, Sutton D M. Thrombotic thrombocytopenic purpura associated with ticlopidine use: a report of 3 cases and review of the literature.  Arch Intern Med. 1999;  159 311-314